JP2013523676A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523676A5 JP2013523676A5 JP2013501779A JP2013501779A JP2013523676A5 JP 2013523676 A5 JP2013523676 A5 JP 2013523676A5 JP 2013501779 A JP2013501779 A JP 2013501779A JP 2013501779 A JP2013501779 A JP 2013501779A JP 2013523676 A5 JP2013523676 A5 JP 2013523676A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- inulin
- solvent
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 229920001202 Inulin Polymers 0.000 claims 8
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 8
- 229940029339 inulin Drugs 0.000 claims 8
- 239000002904 solvent Substances 0.000 claims 7
- 239000004480 active ingredient Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 238000002360 preparation method Methods 0.000 claims 6
- 239000011159 matrix material Substances 0.000 claims 5
- 239000007788 liquid Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical group NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims 2
- 229960001596 famotidine Drugs 0.000 claims 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 2
- 229960003088 loratadine Drugs 0.000 claims 2
- 229960001951 montelukast sodium Drugs 0.000 claims 2
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 claims 2
- 210000003296 saliva Anatomy 0.000 claims 2
- 238000000859 sublimation Methods 0.000 claims 2
- 230000008022 sublimation Effects 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical group C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960004281 desmopressin Drugs 0.000 claims 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical group C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 claims 1
- 229960002845 desmopressin acetate Drugs 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 239000002075 main ingredient Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims 1
- 239000007892 solid unit dosage form Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN742/DEL/2010 | 2010-03-29 | ||
| IN742DE2010 | 2010-03-29 | ||
| PCT/EP2011/054698 WO2011120903A2 (en) | 2010-03-29 | 2011-03-28 | A fast dissolving pharmaceutical composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523676A JP2013523676A (ja) | 2013-06-17 |
| JP2013523676A5 true JP2013523676A5 (enExample) | 2014-04-24 |
| JP5907945B2 JP5907945B2 (ja) | 2016-04-26 |
Family
ID=54241475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501779A Active JP5907945B2 (ja) | 2010-03-29 | 2011-03-28 | 速溶解性医薬組成物 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10086078B2 (enExample) |
| EP (1) | EP2552403B1 (enExample) |
| JP (1) | JP5907945B2 (enExample) |
| KR (1) | KR101725173B1 (enExample) |
| CN (1) | CN102821755A (enExample) |
| AR (1) | AR080736A1 (enExample) |
| AU (1) | AU2011234636B2 (enExample) |
| BR (1) | BR112012024428A2 (enExample) |
| CA (1) | CA2793405A1 (enExample) |
| DK (1) | DK2552403T3 (enExample) |
| ES (1) | ES2553568T3 (enExample) |
| HU (1) | HUE026213T2 (enExample) |
| IL (1) | IL222086A (enExample) |
| JO (1) | JO3112B1 (enExample) |
| MX (1) | MX2012011204A (enExample) |
| NZ (1) | NZ602441A (enExample) |
| PL (1) | PL2552403T3 (enExample) |
| PT (1) | PT2552403E (enExample) |
| RU (1) | RU2566270C2 (enExample) |
| SA (1) | SA111320317B1 (enExample) |
| TW (1) | TWI513477B (enExample) |
| WO (1) | WO2011120903A2 (enExample) |
| ZA (1) | ZA201207176B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12186426B2 (en) | 2009-10-30 | 2025-01-07 | Ix Biopharma Ltd. | Solid dosage form |
| EP2493457B1 (en) | 2009-10-30 | 2017-08-09 | IX Biopharma Ltd | Fast dissolving solid dosage form |
| JO3112B1 (ar) * | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
| CN103781467B (zh) * | 2011-09-16 | 2016-08-31 | 辉凌公司 | 一种快速溶解药物组合物 |
| TW201422254A (zh) | 2012-11-21 | 2014-06-16 | Ferring Bv | 用於速釋及延釋的組成物 |
| CN106456535B (zh) * | 2014-04-25 | 2020-07-03 | R.P.谢勒技术有限公司 | 稳定的孟鲁司特溶液 |
| CA3046725A1 (en) | 2017-01-11 | 2018-07-19 | Ferring B.V. | A fast disintegrating pharmaceutical composition |
| CN111904936B (zh) * | 2020-08-28 | 2022-07-19 | 开封康诺药业有限公司 | 一种法莫替丁冻干粉针剂 |
| CA3194494A1 (en) | 2020-09-29 | 2022-04-07 | Millicent Pharma Limited | Orodispersible formulations |
| WO2022103634A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Improved use of cannabinoids in the treatment of epilepsy |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA251629A (en) | 1925-07-14 | T. Hanna William | Coal cutting knife | |
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| CA1114812A (en) | 1977-08-16 | 1981-12-22 | Carlos Moreno | Hapten polysaccharide conjugates |
| CN1053808C (zh) | 1993-04-24 | 2000-06-28 | 章修纲 | 尼非地平控释剂型 |
| EP0879600A1 (en) | 1997-05-20 | 1998-11-25 | Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) | Fructan containing composition for the prevention and treatment of colon cancer |
| EP0958825A1 (en) * | 1998-05-18 | 1999-11-24 | Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) | Synergistic composition of a non-digestible carbohydrate and an anti-cancer drug for use in the treatment of cancer |
| SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| AU1453600A (en) | 1998-11-04 | 2000-05-22 | Mcneil-Ppc, Inc. | Solid oral dosage forms containing alginic acid and famotidine |
| GB9901819D0 (en) | 1999-01-27 | 1999-03-17 | Scherer Corp R P | Pharmaceutical compositions |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| NL1012300C2 (nl) * | 1999-06-11 | 2000-12-12 | Rijksuniversiteit | Stabilisator voor farmaca. |
| EP1064938A1 (en) | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| JP2003506480A (ja) * | 1999-08-17 | 2003-02-18 | ノバルテイス・コンシユーマー・ヘルス・エス・アー | 急速に溶解する剤形およびその製造方法 |
| WO2002003992A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating prosthesis-related bone degeneration |
| RU2003100532A (ru) | 2000-07-13 | 2004-07-20 | Дайити Фармасьютикал Ко., Лтд. (JP) | Фармацевтические композиции, содержащие соединение соединения dds |
| IT1319664B1 (it) * | 2000-11-17 | 2003-10-23 | Pharma Biotech Ltd | Addotti di antibatterici chinolonici con polimeri polisaccaridicinaturali. |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| MY148466A (en) | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| HRP20040816A2 (en) | 2002-04-03 | 2005-06-30 | Solvay Pharmaceuticals B.V. | Stabilized natural cannabinoid formulation |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| AU2003233118B8 (en) | 2002-05-07 | 2009-07-30 | Ferring Bv | Desmopressin in an orodispersible dosage form |
| WO2003099040A1 (en) * | 2002-05-27 | 2003-12-04 | Advance Holdings Limited | Dietary supplements from wine vinasses and relevant production process |
| US20040096569A1 (en) | 2002-11-15 | 2004-05-20 | Barkalow David G. | Edible film products and methods of making same |
| EP1428526A1 (en) * | 2002-12-13 | 2004-06-16 | Rijksuniversiteit Groningen | Formulation for fast dissolution of lipophilic compounds |
| US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
| WO2004075875A1 (en) | 2003-02-28 | 2004-09-10 | Alk-Abello A/S | Dosage form having a saccharide matrix |
| DK1514553T3 (da) | 2003-09-05 | 2008-06-23 | Myung-Jun Chung | Mælkesyrebakteriepulver, der er dobbeltbelagt under anvendelse af protein og polysaccharid og fremgangsmåde til fremstilling af samme samt dosisform af dette |
| CN100366294C (zh) | 2004-04-30 | 2008-02-06 | 量子高科(北京)研究院有限公司 | 一种口腔速溶制剂及其生产方法 |
| EP1597978A1 (en) | 2004-05-17 | 2005-11-23 | Nutricia N.V. | Synergism of GOS and polyfructose |
| MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
| US20060088593A1 (en) | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
| CN100339081C (zh) * | 2004-11-10 | 2007-09-26 | 范敏华 | 一种氯雷他定口腔崩解片剂的制备方法 |
| TW200621310A (en) * | 2004-11-10 | 2006-07-01 | Univ Groningen | A process for preparing formulations of lypophilic active substances by spray freeze drying |
| WO2006067593A1 (en) * | 2004-12-23 | 2006-06-29 | Mcneil-Ppc, Inc. | Orally disintegrating pharmaceutical compositions with sensory cue agents |
| US20070042023A1 (en) | 2005-08-22 | 2007-02-22 | National Starch And Chemical Investment Holding Corporation | Dissolvable film |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| DK2347775T3 (da) | 2005-12-13 | 2020-07-13 | Harvard College | Skabeloner til celletransplantation |
| US20070293582A1 (en) | 2006-06-05 | 2007-12-20 | Malcolm Hill | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
| FR2910812B1 (fr) * | 2006-12-29 | 2009-03-20 | Pierre Fabre Medicament Sa | Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante |
| WO2008119012A2 (en) | 2007-03-27 | 2008-10-02 | The Procter & Gamble Company | Methods and kits for administering probiotics |
| WO2009002084A2 (en) | 2007-06-27 | 2008-12-31 | Hanmi Pharm. Co., Ltd. | Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same |
| KR100930427B1 (ko) | 2008-01-25 | 2009-12-08 | 정명준 | 3중 코팅 유산균의 제조방법 및 나노 입자 코팅 방법, 그방법으로 제조된 3중 코팅 유산균 및 이를 포함하는 제품 |
| US8623401B2 (en) | 2008-03-27 | 2014-01-07 | Fenwafe Inc. | Wafer formulation |
| BRPI0917172A2 (pt) * | 2008-08-28 | 2015-08-04 | Chr Hansen As | Composição bacteriana |
| EP2552418B1 (en) | 2010-03-29 | 2017-08-09 | Ferring B.V. | A fast dissolving pharmaceutical composition |
| JO3112B1 (ar) * | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
| US20120135050A1 (en) | 2010-07-08 | 2012-05-31 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| CN103781467B (zh) | 2011-09-16 | 2016-08-31 | 辉凌公司 | 一种快速溶解药物组合物 |
| US20150306170A1 (en) | 2012-11-21 | 2015-10-29 | Ferring B.V. | Composition for immediate and extended release |
-
2011
- 2011-03-22 JO JOP/2011/0100A patent/JO3112B1/ar active
- 2011-03-28 PL PL11711526T patent/PL2552403T3/pl unknown
- 2011-03-28 RU RU2012141141/15A patent/RU2566270C2/ru not_active IP Right Cessation
- 2011-03-28 CA CA2793405A patent/CA2793405A1/en not_active Abandoned
- 2011-03-28 DK DK11711526.1T patent/DK2552403T3/en active
- 2011-03-28 WO PCT/EP2011/054698 patent/WO2011120903A2/en not_active Ceased
- 2011-03-28 MX MX2012011204A patent/MX2012011204A/es unknown
- 2011-03-28 HU HUE11711526A patent/HUE026213T2/en unknown
- 2011-03-28 US US13/638,121 patent/US10086078B2/en active Active
- 2011-03-28 ES ES11711526.1T patent/ES2553568T3/es active Active
- 2011-03-28 TW TW100110569A patent/TWI513477B/zh not_active IP Right Cessation
- 2011-03-28 PT PT117115261T patent/PT2552403E/pt unknown
- 2011-03-28 KR KR1020127027215A patent/KR101725173B1/ko not_active Expired - Fee Related
- 2011-03-28 JP JP2013501779A patent/JP5907945B2/ja active Active
- 2011-03-28 NZ NZ602441A patent/NZ602441A/en not_active IP Right Cessation
- 2011-03-28 AU AU2011234636A patent/AU2011234636B2/en not_active Ceased
- 2011-03-28 EP EP11711526.1A patent/EP2552403B1/en active Active
- 2011-03-28 BR BR112012024428A patent/BR112012024428A2/pt not_active IP Right Cessation
- 2011-03-28 CN CN2011800171635A patent/CN102821755A/zh active Pending
- 2011-03-29 AR ARP110101023A patent/AR080736A1/es unknown
- 2011-03-29 SA SA111320317A patent/SA111320317B1/ar unknown
-
2012
- 2012-09-23 IL IL222086A patent/IL222086A/en not_active IP Right Cessation
- 2012-09-25 ZA ZA2012/07176A patent/ZA201207176B/en unknown
-
2018
- 2018-08-29 US US16/115,650 patent/US10512695B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523677A5 (enExample) | ||
| JP2013523676A5 (enExample) | ||
| RU2014105585A (ru) | Быстрорастворимая фармацевтическая композиция | |
| RU2012141140A (ru) | Быстрорастворимая фармацевтическая композиция | |
| RU2012141141A (ru) | Быстрорастворимая фармацевтическая композиция | |
| JP2012255026A5 (enExample) | ||
| JP2011201907A5 (enExample) | ||
| EA201200096A1 (ru) | Фармацевтическая композиция ингибитора протеазы вируса гепатита c | |
| JP2016065086A5 (enExample) | ||
| JP2007506775A5 (enExample) | ||
| PE20181177A1 (es) | Formas de dosis de liberacion controlada encerradas resistentes a manipulaciones indebidas | |
| JP2012502037A5 (enExample) | ||
| JP2008533007A5 (enExample) | ||
| AR076864A1 (es) | Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| JP2016540021A5 (enExample) | ||
| JP2016501828A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| JP2014221827A5 (enExample) | ||
| EA201400679A1 (ru) | Композиция сухого порошка производного азола для ингаляции | |
| JP2011527299A5 (enExample) | ||
| MY160652A (en) | Pharmaceutical composition for oral administration | |
| RU2014115287A (ru) | Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения | |
| JP2015510928A5 (enExample) | ||
| JP2016530316A5 (enExample) |